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Abstract
Background: Given the rising number of asthma cases and the increasing costs of health care, prevention may be the
best cure. Decisions regarding the implementation of prevention programmes in general and choosing between
unifaceted and multifaceted strategies in particular are urgently needed. Existing trials on the primary prevention of
asthma are, however, insufficient on their own to inform the decision of stakeholders regarding the cost-effectiveness
of such prevention strategies. Decision analytic modelling synthesises available data for the cost-effectiveness
evaluation of strategies in an explicit manner. Published reports on model development should provide the detail and
transparency required to increase the acceptability of cost-effectiveness modelling. But, detail on the explicit steps and
the involvement of experts in structuring a model is often unevenly reported. In this paper, we describe a procedure to
structure and validate a model for the primary prevention of asthma in children.
Methods: An expert panel was convened for round-table discussions to frame the cost-effectiveness research
question and to select and structure a model. The model’s structural validity, which indicates how well a model
reflects the reality, was determined through descriptive and parallel validation. Descriptive validation was
performed with the experts. Parallel validation qualitatively compared similarity between other published models
with different decision problems.
Results: The multidisciplinary input of experts helped to develop a decision-tree structure which compares the
current situation with screening and prevention. The prevention was further divided between multifaceted and
unifaceted approaches to analyse the differences. The clinical outcome was diagnosis of asthma. No similar model
was found in the literature discussing the same decision problem. Structural validity in terms of descriptive validity
was achieved with the experts and was supported by parallel validation.
Conclusions: A decision-tree model developed with experts in round-table discussions benefits from a systematic and
transparent approach and the multidisciplinary contributions of the experts. Parallel validation provides a feasible
alternative to validating novel models. The process of structuring and validating a model presented in this paper could be
a useful guide to increase transparency, credibility, and acceptability of (future, novel) models when experts are involved.
Background
Asthma affects more people [1,2] and costs more to
manage than ever before [3-6]. Given limited resources
for competing needs, prevention of asthma could pay
off. Currently, primary prevention programmes on
asthma generally differ in the approach to reduce or
avoid exposure to one (unifaceted, e.g. an anti-house
dust mite [HDM] measure) or more environmental fac-
tors (multifaceted, e.g. exclusive breastfeeding until six
months and an anti-HDM measure) [7].
The decision to ultimately implement asthma preven-
tion programmes, let alone choose between a unifaceted
and a multifaceted approach, is not made easier with
favourable [8,9] and unfavourable [10,11] reports on the
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sions could be due to factors such as the essential differ-
ence between the approaches (unifaceted versus
multifaceted), the population (open versus captive),
“room for improvement” (pre-existing high-levels of
allergen avoidance or adapted smoking behaviour), and
even the selected outcome measures or (asthma) defini-
tions (e.g. asthma-related symptoms, physician-diagno-
sis). However, the meta-analyses by van Schayck and
colleagues [12,13] show that multifaceted programmes
significantly reduce the risk for asthma compared to
unifaceted programmes.
Although several studies have been performed on pri-
mary prevention of asthma amongst children, none
could singly determine the cost-effectiveness of primary
prevention [8-11,14-18]. Specifically, there is no known
study that directly compares th ev a r i o u sa l t e r n a t i v e si n
primary asthma prevention [12,13]. Ideally, it could be
studied in a clinical trial or, alternatively, using a model
which synthesises the evidence from all available sources
and levels of evidentiary quality [19,20]. Such a model
could estimate the uncertainty of decisions and cost
associated with asthma given imperfect, current data in
an explicit and transparent manner [19].
A permutation of models is possible depending on
various considerations but, despite the pervasive use of
models in economic evaluation, there is still wariness
about their appropriateness and validity [19,21]. How-
ever, movement towards uniformity through good prac-
tice guidelines [21-24] have helped to allay such
wariness. Still, there is a need for more transparency
and explicitness in modelling practice [25]. Already, this
is being met in clinical effectiveness research by the
increasing practice of reporting study protocols separate
from the trial results [26,27], which reduces publication
bias and increases transparency and credibility. In this
paper, we describe the design and validation of the
structure of a decision analytic model which compares
multifaceted and unifaceted programmes of primary pre-
vention of asthma in children versus the current situa-
tion (i.e. unstructured advice on avoiding allergen
sensitization and symptomatic treatment).
Methods
Expert panel sessions and model structuring
Consultation with experts, just as personal experience or
a review of the literature, may provide the background
information needed when developing a model [28]. For
this paper, experts were consulted to provide biomedical
insight into the natural course of asthma and its care in
the Netherlands. We developed a protocol (Additional
File 1) on conducting the expert panel held as round-
table sessions [29]. The protocol identified relevant
inputs and expected outcomes of each session, including
the guiding questions to structure the discussions. Fol-
lowing a review of relevant health technology assess-
ment (HTA) literature [28-30], the protocol consists of
the following elements:
1. Description of the study’s background, motivation,
and objectives including the role of experts in the
modelling process;
2. Identification of criteria for selecting experts;
3. Identification and inclusion of experts;
4. Identification of the number and purpose of the
expert sessions;
5. Description of the structure of the sessions in
terms of knowledge, process events, and expected
session outcomes;
6. Description of the techniques to referee between
experts, including the feedback communication with
the experts; and
7. Documentation of the results.
The foremost criterion for expert selection was the
extent of their expertise and experience with asthma
and its prevention in children and/or research experi-
ence in the field of efficacy and cost-effectiveness [29].
This was discussed within the research group which
resulted in nominations for candidate experts. Once
identified and contacted, the experts’ willingness to par-
ticipate and ability to attend the sessions [29] were also
considered. The experts received copies of the protocol
for their guidance to the process. Initially, only two ses-
sions were planned but because of logistical issues as
well as significant changes in the model structure after
consulting the research group, another session was
added. Consensus was not formalised as strict unanimity
on discussion points because of the explorative nature of
the round-table discussions [29].
The expert panel sessions were conducted in 2010 at
Maastricht University, the Netherlands. Eight expert
nominees were contacted but the final combination of
experts were two from general practice and (paediatric)
pulmonology and one each from epidemiology and
HTA. During the first session, the HTA expert joined in
by telephone and thereafter kept contact through e-mail.
Because of unavailability, one pulmonologist and one
general practitioner (GP) dropped out after the first and
second sessions, respectively.
The first session was meant to frame the decision pro-
blem and generate assumptions needed to determine the
structure of the model. Input to this session was an
overview of the research line as background for the
decision problem and purpose of the model. The experts
were asked about other aspects of the decision frame-
work covering the natural history of the disease, gold
standards of measure, possible interaction and recursion
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Since time horizon, population, and perspective were
already naturally defined by the existing clinical studies
f r o mt h eP R E V e n t i o no fA S t h m aa m o n g s tC h i l d r e n
(PREVASC) research line [14-18], these elements were
not solicited from the experts. The first session resulted
in a set of assumptions and a decision framework.
After the first expert panel session, the literature was
systematically searched for existing models that could be
adapted for the current decision problem [31]. When a
new model was required, the type was chosen using
guidelines and recommendations in the literature
[21-24]. Consideration was given to the purpose (single-
use vs. programmatic), level of simulation (individual vs.
cohort), relationship between individuals (independent
vs. interacting), and frequency of outcomes/health states
(recursive vs. non-recursive). The model structure was
drawn based on the type of model, the decision frame-
work and assumptions, and published recommendations
[32].
The last sessions were meant to refine the model
structure and determine its descriptive validity. For the
second session, the input was an overview of the model-
ling process and the general types of models, to provide
some information to the experts with limited exposure
to economic modelling. It was only given at that time so
that the generation of assumptions and the framing of
the decision problem during the first session would not
be restricted by bias for one model or another. During
this second session, the model structure was scrutinised
on how well it reflected the set of assumptions and deci-
sion framework from the first expert panel session. The
outcome at this stage was a list of comments for
improving the correspondence of the model structure
with the set of assumptions and decision framework. On
the third and last expert panel session, the input was
the latest model structure which was again evaluated.
After satisfying the descriptive validity, the model was
finalised.
Validating the model
Descriptive validity (i.e. whether the essential character-
istics of reality is captured in the model [33-35]) was
determined during the second and third expert panel
sessions. This validation was carried out with the
experts’ review of how the model structure was able to
incorporate the assumptions about the development and
current care of the disease into a simplified structure.
Specifically, it was determined during the sessions
whether the model was parsimonious and sufficient to
answer the decision problem [36]. This was an iterative
process with the experts after the initial session.
In the absence of comparable models that evaluate
allergen-avoidance measures in the primary prevention
of asthma in children, we focused instead on the paralle-
lisms (i.e. similarities) between characteristics of the
model structure, namely: model type, time horizon, per-
spective, population, intervention, comparator, and
health states/effect measures [37]. The other characteris-
tics are related to the natural history of a disease and its
treatment which are currently important determinants
in the chain of choices that lead to the selection of the
model structure [37]. Aside from including studies on
the secondary and tertiary prevention of asthma (i.e.
preventing allergic sensitisation from progressing to
asthma or preventing the exacerbations of established
asthma [1]) we proceeded with this “parallel validation”
by increasing the scope to studies on lower respiratory
tract infections. These infections in infants, particularly
with the respiratory syncytial virus, have been associated
with the development of asthma later on [38]. To test
for the parallelisms, we first performed a systematic
search of the literature to identify the relevant studies.
The search was conducted in the PubMed databases
based on an extensive search strategy for economic eva-
luations [39,40]. The database was searched until 08
September 2010 and was restricted to English-language
records of titles and abstracts of evaluations that used
decision-analytic modelling. Only evaluations of at least
two alternatives on asthma prevention which relate
costs to consequences [41] were included in the review.
Following the screening process (Figure 1), the results
were reviewed by one of the co-authors and any uncer-
tainty was resolved by direct discussion. Technical or
internal validity of the calculations and consistency of
formulae and parameter inputs with the assumptions
were checked.
Model operation
Once the decision problem was framed and the model’s
structure visualised, its operational feasibility or techni-
cal validity [35] was tested by populating it with data
from the PREVASC studies. Detailed description of the
PREVASC programme (Figure 2) can be found else-
where [14-18]. Children were included in the studies
based on risk for first-degree familial asthma history (i.e.
positive or negative, PFH or NFH respectively) [14,15].
Phase 1 and 2 studies investigated the clinical effects of
multifaceted primary asthma prevention at age two and
six years, respectively. It was found that over the short
or long term, there were no significant reductions of
asthma diagnosis between intervention and control
groups [16]. However, a subgroup of the PREVASC chil-
dren seemed to benefit from the prevention programme
[14]. Phase 3 was a natural history study which found
that there were more respiratory-tract morbidities and
atopy in PFH than NFH children in the first two years
of life [19,20].
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Page 3 of 14Branch probabilities were calculated as the ratio of one
situation over its sum with the complement possibilities. A
diagnostic algorithm (Table 1) was applied to determine
asthma status based on inhaled corticosteroid (ICS) use,
wheezing three months prior to the lung function measure-
ments, and the measurements on reversibility and hyper-
reactivity. Because the original PREVASC clinical studies
did not explicitly study the effects of unifaceted prevention,
this had to be derived from the clinical data. A per-protocol
analysis of compliance was used to reclassify PFH partici-
pants into multifaceted, unifaceted, or control. The current
situation was a combination of the PFH control and NFH
participants weighted by the respective ratios of 20% and
80% found in the general population [42].
Prevention of asthma
in children?
YES
NO NO Prevention of lower
respiratory tract
infection in children?
Costs and consequences
brought in relation with
each other?
Comparison between two
or more alternatives?
Full, English-language
article available?
Abstract available?
NO
NO
NO
NO
YES
YES
YES
YES
 Use of decision analytic
modelling?
YES
PAPER INCLUDED
YES
PAPER EXCLUDED
NO
Figure 1 Selection of economic evaluations for the modified convergent validation. This flow chart shows the process of selecting the
studies which would be included in the analysis for parallel validation.
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assessed and valued using standardised unit prices for
the Netherlands indexed using 2009 figures [43].
These direct medical costs include GP and specialist
consultations for asthma-related complaints, any
related hospital admissions, the diagnostic tests (i.e.
chest x-ray and radioimmunoassay test for allergens),
and medication use. For those who received interven-
tion, costs on research nurse visits, the use of house
dust mite-impermeable materials for the beds of parti-
cipants and parents, hypoallergenic formula feeding,
and education materials in the form of brochures
were included. The model outcome was the incremen-
tal cost-effectiveness ratio which was assessed for var-
ious threshold values (€0-€70,000 per asthma case
avoided).
Results
Expert panel and sessions
Clinical insight into the natural course of asthma, diag-
nosis, as well as current care and alternatives were pro-
vided by experts from the first three fields. The HTA
expert provided insight into important economic consid-
erations such as how costs and consequences can be
incorporated in the comparison of alternatives. The
involvement of the experts in the development of the
model structure is illustrated in Figure 3.
Decision framework and assumptions for the model
structure
Discussion amongst the experts resulted in a decision
framework (Table 2) that determined the most appropri-
ate model. This framework was incumbent on a number
N=221 N=308
N=220 N=224 N=111 N=107
Legend: - Randomisation - Administration of Intervention - Measurement point PFH/NFH - Positive/Negative first-degree familial asthma history
4th mo.
BIRTH
1st yr.
2nd yr.
3rd yr.
4th yr.
5th yr.
 ~6th yr. PART 2 STUDY
PART 4 STUDY
PART 1 STUDY PART 3 STUDY N=219
Screening by general
practioner for first-degree
familial asthma history
and Recruitment
N=793
An open, registered population from
78 general practice surgeries
in the Netherlands
N=140,000
N=476
Positive (PFH)
N=317
Negative (NFH)
Intervention
N=242
Short-term
N=108
Long-term
N=111
Control
N=234
R
R
R
EXCLUSION CRITERIA:
Third trimester gestational status of the foetus
Intra-uterine/neonatal deaths
Major language problems
Serious birth defects (illness or malformations)
Moving abroad
SELECTION CRITERIA:
Referral of pregnant women
by general practitioners
and midwives
Figure 2 The PREVASC Research Line. Schematic flow of the participants in the different studies of the PREVASC research line beginning with
the risk-screening of the sample population indicates that data synthesis through modelling is necessary to determine the value of multifaceted
primary asthma prevention amongst children. Measurement around the age of six for subjects with negative history is part of the current (Phase 4)
study.
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biomedical model of asthma. The experts considered
asthma to be more than the sum of genetic expression
and environmental influences that might be best
addressed by multifaceted programmes. They estimated
clinicians would see a larger number of allergic children
with transient wheezing than the classic asthma presen-
tation of persistent wheezing combined with shortness
of breath and (nocturnal) coughing. Most asthma cases
that would be seen, they thought, would be the allergic
variant typically seen in children exposed to common
allergens for the first time. The experts argued that the
processes that lead to asthma may have begun with
allergic sensitisation in utero. They cited that the cur-
rent paradigm of asthma prevention in the Netherlands
consists of unstructured pre- and post-natal advice to
mothers and their families regarding exposing the child
to environmental tobacco smoke and air-borne particu-
lates for children in general and pharmacotherapy for
those with symptoms. The experts assumed that any
alternative intervention must also be instituted during
gestation and after birth to prevent asthma. For any pre-
vention programme, a reasonable screening strategy is
necessary to identify the recipients who are most at risk
and stand to gain the most from the programme. It was
thought that this would be best done through first-
degree familial asthma history.
Although differentiating between phenotypes was
recognised as invaluable in refining asthma diagnosis, it
was contended that the diagnosis of asthma alone was
sufficient and necessary to determine the value of pri-
mary prevention at the health care level. Even if diagno-
sis were to be established at age six years, it was
a s s u m e dt h a tt h ep a t h o l o g ical processes may have
begun long before diagnosis. Furthermore, these pro-
cesses may continue even in the absence of clinical
signs and symptoms at later years. However, they noted
that diagnosis of asthma prior to age six years is difficult
or changes over time. Patients would be seen when the
f l a r eo fs y m p t o m sa sw e l la st h ep a t h o l o g i cp r o c e s sa r e
s u b s i d i n gw h i c hm a yn o tg i v eav e r ya c c u r a t ep i c t u r eo f
the disease. At a later age, clinical remission may occur
during pubescence or it may recur during the adult
years. The difficulty, they said, is compounded by a lack
of gold standard for its diagnosis. Around age six years,
large groups of children who may have asthma are
symptom-free but physiologic changes such as exagger-
ated inflammatory reactions and airway remodelling
may already be occurring which could be detected using
objective measurements. According to the experts,
bronchioalveolar lavage and biopsies are the most reli-
able tests for airway inflammation. But since the proce-
dures are also invasive and difficult to perform in
practice, those were considered primarily research more
than routine clinical tools. In contrast, the experts said
that spirometry is common in the general practice set-
ting and suitable in documenting abnormal lung func-
tion described by reversibility and hyperresponsiveness
of the bronchial tubes. Combining objective lung func-
tion tests with symptomatology seemed to them to be
the best approach to asthma diagnosis to date. However,
they said that since symptomatic children in the Nether-
lands receive asthma medication, particularly ICS, an
objective diagnosis at age six years may be contami-
nated. It was then assumed that children who received
ICS therapy three months prior to the tests are asth-
matic when either test of reversibility or hyperreactivity
is positive. When both tests are negative, diagnosis
could go either way. Amongst children who did not
receive ICS therapy, positive hyperreactivity was
assumed to signify presence of asthma and negative
hyperreactivity meant absence of asthma. It was also
Table 1 Algorithm for objective asthma diagnosis of children
Inhaled corticosteroid treatment 3 months prior to lung function
assessment
Symptom/
Complaint
Reversibility Hyperreactivity Asthma
- + + Not Needed +
+- + +
+- - -
-+ + +
-+ - -
- - Not Needed -
+ Not
Needed
++ +
Not
Needed
+- +
Not
Needed
-+ +
Not
Needed
- - Sensitivity
Analysis
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Page 6 of 14assumed that evaluating the costs and consequences
over a time horizon of six years after birth would be suf-
ficient since this is the age when lung function tests
would be first reliable in children.
Model structure
A search of the literature for economic models of pri-
mary asthma prevention in children based on the
expert-developed decision framework came up empty-
handed (Table 3). This meant that a new model (Figure
4) had to be developed which began with the problem
or situation of administering to children a primary pre-
vention programme on asthma. Based on the expert ses-
sions, it was determined that the decision tree structure
suited the decision framework and assumptions. Identi-
fying the target population for the intervention on the
Identify
the decision
problem
Frame
the decision
problem
1st Session
Expert Panel
Search for
models with similar
problems
Use the
(modified) extant
structure
Yes
No
Extant?
2nd & 3rd Sessions
Expert Panel 
Construct
the model
Finalise
the
model
Restructure
the
model
Select the
appropriate model
(or type)
Validate 
the model
Yes
No
Valid?
Determine
the model
assumptions
Figure 3 Expert input in the model development. Flowchart showing the influence of experts regarding the design and validation of the
structure of the model to determine the economic value of primary prevention in asthma.
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Page 7 of 14basis of risk became the first node for the intervention
arm of the decision tree. It was assumed that NFH chil-
dren would receive current care [44] whereas PFH chil-
dren would be given the intervention either as a
unifaceted or multifaceted prevention depicted by the
second decision node coming from the PFH branch. A
child would receive unifaceted prevention when only
one measure against air- or food-borne allergens is
employed and multifaceted when at least two measures
against both triggers are used. It was also assumed that
children could not shift between these two prevention
categories. The model resulted in three situations of
care: prevention with unifaceted or multifaceted
approach and current situation care. For these situa-
tions, children were assumed to either remain healthy or
manifest some asthma signs and symptoms. Consequent
upon the clinical picture, the children may or may not
receive pharmacotherapy as required. The primary out-
come is either a positive or a negative objective diagno-
sis of asthma, which relies on reversibility and
hyperreactivity tests and symptomatology.
Validation of the model structure
The model structure was revised and refined in the last
two sessions with the experts who were asked to con-
sider the intuitiveness of the model structure in reflect-
ing the decision framework and the assumptions. The
review was at the same time a process of descriptively
validating the model structure. Concerning the parallel
validity with models in the literature, the strategy and
Table 2 Decision problem framework for the primary prevention of asthma in children
Framework Aspect Detail
Objective(s) To reduce the incidence of asthma diagnosis in children
To reduce the costs associated with asthma health care
To determine the value of first-degree familial asthma history as a risk indicator
Audience/Stakeholder
(s)
Primary care givers (primary care or welfare centre physicians, midwives, and general practice/medical assistants) and Medical
specialists (pulmonology and paediatrics)
Perspective Healthcare system
Analytic time horizon Up to six years after birth
Intervention(s) Multifaceted primary prevention
Unifaceted primary prevention
Comparator Usual care
Target population Unborn child
Effect outcome(s) Objective diagnosis of asthma
Secondary: Functional status; Serum IgE levels as index of exposure to allergens from house dust mites, cats, and dogs
Cost(s) Direct health care costs;
Intervention costs
Economic evaluation Cost-effectiveness
Table 3 Results for the systematic review for decision analytic models on asthma prevention
Step Search String Hits
#1 ("Costs and Cost Analysis/classification"[MeSH] OR “Costs and Cost Analysis/economics"[MeSH] OR “Costs and Cost Analysis/
education"[MeSH] OR “Costs and Cost Analysis/ethics"[MeSH] OR “Costs and Cost Analysis/history"[MeSH] OR “Costs and Cost
Analysis/legislation and jurisprudence"[MeSH] OR “Costs and Cost Analysis/methods"[MeSH] OR “Costs and Cost Analysis/
organization and administration"[MeSH] OR “Costs and Cost Analysis/standards"[MeSH] OR “Costs and Cost Analysis/statistics and
numerical data"[MeSH] OR “Costs and Cost Analysis/trends"[MeSH] OR “Costs and Cost Analysis/utilization"[MeSH])
26349
#2 Cost-effective*[Title/Abstract] 54952
#3 #1 OR #2 78623
#4 Journal Article[ptyp] AND English[lang] 14875628
#5 “Animals"[MeSH:NoExp] 4570915
#6 “Humans"[MeSH:NoExp] 1125512
#7 #5 NOT (#5 AND #6) 3397345
#8 (#3 AND #4) NOT #7 67344
#9 Asthma*[Title/Abstract] or “Asthma/prevention and control"[MeSH] 99545
#10 #8 AND #9 586
#11 #10 NOT Review[Ptyp] 406
#12 “primary prevention"[Title/Abstract] or “secondary prevention"[Title/Abstract] 16821
#13 #11 AND #12 2
#14 #10 AND model[Title/Abstract] 62
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Page 8 of 14resulting hits are shown in Table 3. In reviewing the
titles and abstracts, none of the 406 search results
referred to a trial-based economic evaluation of primary
or secondary asthma prevention in children which used
a non-pharmacological approach. When the survey
focused on models, there were 62 hits, of which only
seven were studies on the pharmacological prevention
of asthma or lower respiratory tract infection in
PRIMARY
PREVENTION
OF ASTHMA
IN CHILDREN
1˚ FAMILIAL ASTHMA
RISK SCREENING
& PREVENTION
MULTIFACETED
PREVENTION
CURRENT SITUATION
- Decision Node Legend: - Probability Node - Action/Activity
ADVICE
UNIFACETED
PREVENTION
(+) 1˚ FAMILIAL
ASTHMA HISTORY
(–) 1˚ FAMILIAL
ASTHMA HISTORY
(+) SYMPTOMS
(+) OBJECTIVE ASTHMA DIAGNOSIS
AROUND AGE SIX YEARS
(–) OBJECTIVE ASTHMA DIAGNOSIS
AROUND AGE SIX YEARS
(–) SYMPTOMS
TREATMENT
NO TREATMENT
(+) OBJECTIVE ASTHMA DIAGNOSIS
AROUND AGE SIX YEARS
(–) OBJECTIVE ASTHMA DIAGNOSIS
AROUND AGE SIX YEARS
(+) SYMPTOMS
(+) OBJECTIVE ASTHMA DIAGNOSIS
AROUND AGE SIX YEARS
(–) OBJECTIVE ASTHMA DIAGNOSIS
AROUND AGE SIX YEARS
(–) SYMPTOMS
TREATMENT
NO TREATMENT
(+) OBJECTIVE ASTHMA DIAGNOSIS
AROUND AGE SIX YEARS
(–) OBJECTIVE ASTHMA DIAGNOSIS
AROUND AGE SIX YEARS
(+) SYMPTOMS
(+) OBJECTIVE ASTHMA DIAGNOSIS
AROUND AGE SIX YEARS
(–) OBJECTIVE ASTHMA DIAGNOSIS
AROUND AGE SIX YEARS
(–) SYMPTOMS
TREATMENT
NO TREATMENT
(+) OBJECTIVE ASTHMA DIAGNOSIS
AROUND AGE SIX YEARS
(–) OBJECTIVE ASTHMA DIAGNOSIS
AROUND AGE SIX YEARS
(+) SYMPTOMS
(+) OBJECTIVE ASTHMA DIAGNOSIS
AROUND AGE SIX YEARS
(–) OBJECTIVE ASTHMA DIAGNOSIS
AROUND AGE SIX YEARS
(–) SYMPTOMS
TREATMENT
NO TREATMENT
(+) OBJECTIVE ASTHMA DIAGNOSIS
AROUND AGE SIX YEARS
(–) OBJECTIVE ASTHMA DIAGNOSIS
AROUND AGE SIX YEARS
- Terminal Node
ADVICE
Figure 4 The PREVASC Decision Tree. Structure of the decision analytic model to assess the cost-effectiveness of primary prevention of
asthma. The tree compares current situation without primary prevention with the alternative of primary prevention of asthma amongst children
(first decision node) as well as whether multifaceted or unifaceted primary prevention approaches is more cost-effective (second decision node).
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Page 9 of 14children. After a critical appraisal, two studies were
further excluded because they did not use decision ana-
lytic models in the economic evaluation. Of the remain-
ing five studies (Table 4), three [45-47] used decision-
tree models and two [48,49] used Markov models. Two
studies focused on asthma prevention [46,49] and others
on RSV infection [45,47,48]. Omnes and colleagues [46]
reported a model which has the most characteristics
similar to ours in terms of model structure, time hori-
zon, perspective, population, comparator, and effects.
The intervention was, however, not a perfect correspon-
dence which is not surprising given the lack of compar-
able models with our decision framework. In short, their
study supports the structural validity of our model and
decision problem’s most salient concerns and so vali-
dates in a way the structure of the model presented
here through parallelisms.
Model operation
For this demonstration of the model’so p e r a t i o na n d
internal validity, we have used solely the data from the
PREVASC studies. Only cases with relevant diagnostic
data were included in the modelling which whittled
down the possible 443 PFH cases in the intervention
and control group to 324 cases. Their compliance with
at least two, one, or none of the measures against expo-
sure to airborne and food allergens was the basis for
respectively regrouping them into multifaceted (N =
259), unifaceted (N = 53), and control (N = 12). Branch
probabilities were calculated and folded back for the
expected outcomes and costs. Between the prevention
approaches, the multifaceted had a higher costs but also
a higher expected probability of asthma cases avoided
than the unifaceted approach (€539.49 vs. €445.19 for
costs and 0.93191 vs. 0.92610 for probability of asthma
avoidance, respectively). This means that the multifa-
ceted approach costs around €16,000 more to avoid one
asthma case than in the unifaceted approach. However,
when compared with the current situation, which has
the lowest cost and highest probability (€302.30 and
0.96494), the two prevention approaches were strongly
dominated. Even for various cost-effectiveness thresh-
olds, the current situation dominated the two
approaches.
Discussion
The model structure
Use of models in health economic evaluation has
increased over the years and most often for one of two
things [50]. First, when the relevant clinical trial has not
(yet) been conducted or economic data is missing or
incomplete. Second, when the clinical trial used inter-
mediate outcomes or when the follow-up period is short
whilst the decision problem is concerned with endpoints
long into the future. Though modelling allows decision
makers to be critical and realistic about alternatives, to
be conscious and clear of valorisation, and to reveal the
relationships between inputs and outputs [51], models
can seem like “black boxes” [33,50] to consumers unless
steps are made explicit and transparent. This was the
rationale for explicitly reporting the steps we took in
structuring our model.
Table 4 Important characteristics of studies for parallel validation
Study Model Time
Horizon
Perspective Population Intervention Comparator Effects
Nuijten [45] Decision tree Lifetime UK National
Health
Service and
society
Pre-term infants and
children with BPD
Palivizumab No
prophylaxis
Number of RSV
hospitalizations
avoided
Omnes [46] Decision tree 7 years (6
years-
adults)
French
Social
Security
Children and adults Specific
immunotherapy
(injectable and
sublingual)
Current
symptomatic
treatment
Proportions of
individuals with
rhinitis or allergic
asthma
Resch [47] Decision tree Lifetime Austrian
third party
payer and
society
Infants born premature
or with BPD, and
children with congenital
heart disease
Palivizumab No
prophylaxis
Life years gained
and QALY
gained
ElHassan [48] Markov (with and
without increased
asthma risk due to
RSV infection)
1 year (no-
risk); 8-10
years (with
risk)
US society Premature infants Palivizumab No
prophylaxis
QALY gained
Brüggenjürgen
[49]
Markov model 15 years German
third party
payer and
society
Children (6 to 12 years),
adolescents (13 to 18
years), and adults (19 to
65 years)
Specific
immunotherapy
(subcutaneous) and
symptom treatment
Symptom
treatment
QALY gained
QALY-quality-adjusted life year.
BPD = bronchopulmonary dysplasia; RSV = respiratory syncytial virus; QALY = quality-adjusted life years
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eral studies [8-11,14-18] have provided information on
effectiveness but none could singly determine whether
primary prevention of asthma is cost-effective and
whether a unifaceted or a multifaceted approach is bet-
ter. Like others [52,53], we have found that the literature
is surprisingly silent regarding health economic studies
on the value of health care strategies other than those
concerned with asthma control. Consequently, one may
cast a wary eye on the policy and care decisions relating
t ot h ep r e v e n t i o no fa s t h m ai nc h i l d r e na n dq u e s t i o n s
whether the decisions were adequately informed. By
synthesising the best available evidence through this
model, we hope to take the first step toward properly
evaluating and substantiating the choice amongst pri-
mary asthma prevention alternatives.
A number of structures could have been used in
developing an economic model from regression equa-
tions to system dynamic models [21-24]. Some of the
more common structures include decision trees, Mar-
kov-types, and discrete event simulations (DES)
[21-24]. It has always been advocated that the choice
of a model structure should be on the consideration of
the simplest, and thus best, fit [34] between three ele-
ments: the decision problem, natural history of the dis-
ease, and current paradigms of care [33]. Since
Markov-type models are used in decision problems
with time-dependent or recurrent situations [21-24],
these were considered inappropriate for this study pri-
marily because asthma was assumed to be a stable
diagnosis. Although asthma is understood to be a
chronic condition, we considered that its diagnosis
would not change in the six-year time frame of our
study. This consideration is supported by findings that
physiologic changes occur even for so-called mild
cases who are more likely to be asymptomatic or only
rarely symptomatic [54]. The various wheezing pheno-
types could have been modelled instead as the recur-
ring disease states of asthma because of their strong
relationship with each other. Despite this, the experts
did not think that wheezing was strictly causative of
asthma. DES structures, which are more detailed and
complicated extensions of Markov-type models
[21-24], are similarly not appropriate for this study
because asthma does not have a universally accepted
measure of severity particularly in population-based
studies [55]. Also, the choice for a more complex
model should be balanced by any change to the results
compared to use of a simpler model [33]. For these
reasons, in combination with the decision framework,
a decision tree structure was chosen and developed for
our specific research question that aims to assess the
cost-effectiveness of a programme to prevent the pre-
sence of asthma in children around age six years.
The current cost-effectiveness analysis limited itself to
the use of the clinical data from the PREVASC studies
to demonstrate the model’s operation and evaluate its
internal validity. The resul t so ft h i sd e m o n s t r a t i o n
showed that based on the probability of developing
asthma, the current situation dominated either approach
to primary prevention of asthma in children. It is nota-
ble though that a multifaceted approach was better than
a unifaceted one. Use of the PREVASC data enabled
technical validation by debugging and refining the
model to handle problems like empty cells. For this fea-
sibility assessment of the model, it should be noted that
originally, there was no distinction made between the
unifaceted and multifaceted groups in the PREVASC
studies. The distinction was made only between control
and intervention.
Value of expert panels
Experts are frequently involved in modelling studies to
provide the initial model structure, validate the final
structure, estimate values of transition probabilities,
usage, and cost units [29]. Their reported involvement
is, however, uneven [25]. Many are unclear in their
reports even of the extent of expert participation in the
process. In this paper, we have presented a detailed
account of the explicit inputs from experts and their
role in structuring a model. We have taken a naïve
approach to reduce the bias of the modeller in the selec-
tion of one model structure over another but more
importantly to benefit from the multi-disciplinary inter-
action between experts. The round-table discussions
provided the opportunity for a dynamic engagement of
the experts critical to framing the decision problem.
Through the multidisciplinary experts, we hope to have
gained better insight into daily practice which is not
always possible through systematic reviews alone. All of
these should contribute to the improvement of the
descriptive and eventual face validity of the model’s
structure through the iterative reflection on the elicited
assumptions. An important consideration is the selec-
tion of experts since the breadth and depth of their
(practical) knowledge would determine the richness of
the endeavour. This could be aided by a brief review of
the literature to identify potential experts who are often
cited.
Eliciting information and feedback from a panel of
experts may range from informal consultations, to
round-table discussions, and then Delphi approaches
[25,29]. The first approach simply and usually provides
background information which may or may not be used.
It is typically unilateral and high-handed. Round-table
discussions are usually semi-structured sessions where
participants are less restricted to explore issues and
arguments without necessarily concluding in a
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Although Delphi approaches may be seen as the most
“democratic” approach to elicit expert opinion because
of the intermediary, it is also a handicap since some ele-
ment of exploration is lost as statements or opinions are
“edited” by the intermediary. In round-table discussions,
model developers may benefit from the dynamic and
personal interaction with and amongst the experts so
that no significantly relevant opinion, alternative, or sce-
nario is left out of the model. There is, however, a
caveat to round-table discussions: more dominant
experts may “drown” the opinions of other experts so
the modeller must be able to deftly control the panel.
We have tried to address this partly through the imposi-
tion of a time limit for the discussions. Also, contribu-
tions of each expert were actively sought.
Parallel validation
Given that novel models do not have comparable mod-
els on the same decision problem, the standard valida-
tion techniques on the face, convergent, and predictive
attributes of this model could not be ascertained at this
stage of our study. The comparison of the outputs
between the developed model and other models on the
same decision problem [33-35] usually covered in the
discussion section of a scientific report [56] hints at the
prevalent approach to validate novel models. Indeed,
validation of novel models “is superseded by the concept
of model credibility” particularly because complete vali-
dation of a model is not possible [57]. Face validity
through expert opinion has been suggested as an
approach to validate the structure of novel models.
Another solution that we propose and have described
h e r em a yb et h r o u g hd r a w i n g parallelisms with other
models, which is to perform what we refer as “parallel
validation”. Similar to convergent validation in testing
between model corroboration [33-35], the distinguishing
feature of parallel validation stems from the absence of
a model built around the same decision problem. The
proposed validation compares other models with the
same structure but concern different diseases, popula-
tions, or interventions. This is therefore a qualitative
consideration of the parallelisms from one model to
another. Structural comparisons are admittedly more
difficult than comparing input parameters [58]. Never-
theless, decision makers still need to make judicious
choices with the highest possible level of confidence.
Existing standards on modelling and reporting have
been used to serve as markers of similarity and dissimi-
larity [59]. Figuratively, one can speak of models on the
same decision problems as coming from one nuclear
family. Parallel validation may be a viable way to com-
pare the structure of one model to a model from a dif-
ferent but closely related family, even if only
qualitatively. How modest the literature on (cost-) effec-
tiveness of pharmacotherapies may be, there is even less
on prevention [52-54]. Parallel validation reveals that
more needs to be done to increase the literature on eco-
nomic evaluation of primary prevention of asthma
amongst children.
Conclusions
In this paper we showed that a decision-tree structure
developed with experts in round-table discussions is
descriptively valid in reflecting reality. In addition it is
able to incorporate the probable scenarios that would
help determine the value of primary asthma prevention.
By explicitly detailing the steps in the development of a
model from initial problem to final structure, the trans-
parency and use of models for economic evaluation may
increase and enrich the toolbox of decision-makers who
need to take informed choices. Future studies could
determine the number and method of panel sessions
that would increase a model’s structural validity.
Additional material
Additional file 1: Protocol Expert Panel Sessions. A copy of the
protocol to conduct the expert panel sessions.
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